

| 货号 | KPTX241 |
|---|---|
| 品牌 | ProteoGenix |
| 样本类型 | Plasma, Serum |
| 检测范围 | 31.25 - 2,000 ng/mL |
| 保存溶液 | When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%. For unopened kits, if you want to prolong the storage time, please store the Standard, Detection A, Detection B and Microplate at - 20℃, the rest reagents should be store at 4℃. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| 检测方法 | Colorimetric |
| 实验类型 | Quantitative |
| 回收率 | 80-120% |
| 运输 | 2-8 ℃ |
| 规格 | Urelumab |
| 别名 | BMS-663513, CAS: 934823-49-1 |
| 背景 | Urelumab is a fully humanized agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Urelumab specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer-Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb-derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex. In December 2008, enrolment was stopped for all urelumab studies following the occurrence of two hepatotoxicity-related deaths. Several years later, the clinical study on Urelumab was restarted. At present, the approval of the monoclonal antibody has not been disclosed in the relevant drug approval agency. |
| Note | For Research Use Only. |

24小时产品查询

扫一扫关注我们

专属渠道经理
